MPN treatment: traditional, new and upcoming drug insights
Myeloproliferative neoplasms (MPNs) have traditionally been treated with hydroxyurea, which remains the gold standard of treatment. Excitingly, there are now novel treatments available in the clinic and more in the pipeline. In this insightful interview, Tiziano Barbui, MD, from Hospital Papa Giovanni XXIII, Bergamo, Italy, discusses the different therapies and the evidence backing their usage in different groups, including interferon and JAK2 inhibitors. This video was recorded at the Myeloproliferative Neoplasms Advances Day 2017 in London, UK.
Get great new content delivered to your inboxSign up
Thrombosis risk factors in MPNs
Genetic mutations may alter treatment courses for patients with MPNs
What is the best therapy for a young patient with relapsed/refractory CLL?
Encouraging patients to ask about clinical trials
Increasing awareness and funding for metastatic breast cancer
More from Tiziano Barbui